Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer

Neutropenia is a common side effect associated with nab-paclitaxel gemcitabine (Nab-Gem) therapy. We retrospectively investigated the association between neutropenia induced by first-line Nab-Gem and survival in metastatic pancreatic carcinoma patients. Metastatic pancreatic patients treated with fi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scientific reports 2020-11, Vol.10 (1), p.19281, Article 19281
Hauptverfasser:	Roviello, Giandomenico, Ramello, Monica, Catalano, Martina, D’Angelo, Alberto, Conca, Raffaele, Gasperoni, Silvia, Dreoni, Lorenzo, Petrioli, Roberto, Ianza, Anna, Nobili, Stefania, Aieta, Michele, Mini, Enrico
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67 631/67/1059 631/67/1059/99 Aged Aged, 80 and over Albumins - administration & dosage Albumins - adverse effects Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Disease-Free Survival Female Gemcitabine Humanities and Social Sciences Humans Male Metastases Metastasis Middle Aged multidisciplinary Multivariate analysis Neoplasm Metastasis Neutropenia Neutropenia - chemically induced Neutropenia - mortality Neutropenia - pathology Paclitaxel Paclitaxel - administration & dosage Paclitaxel - adverse effects Pancreatic cancer Pancreatic carcinoma Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Retrospective Studies Science Science (multidisciplinary) Statistical analysis Survival Survival Rate Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Neutropenia is a common side effect associated with nab-paclitaxel gemcitabine (Nab-Gem) therapy. We retrospectively investigated the association between neutropenia induced by first-line Nab-Gem and survival in metastatic pancreatic carcinoma patients. Metastatic pancreatic patients treated with first-line Nab-Gem were included in this retrospective analysis. Neutropenia was categorized using the National Cancer Institute Common Toxicity Criteria scale. Outcome measures were overall survival (OS), progression-free survival (PFS) and response rate. 115 patients were analyzed. Median PFS was 7 months (95% CI 5–8) for patients with grade ≥ 3 neutropenia and 6 months (95% CI 5–6) for patients with grade
ISSN:	2045-2322 2045-2322
DOI:	10.1038/s41598-020-76465-9